Please assess the completion status of the following clinical trial:

Trial Title: FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed neuroendocrine carcinoma of the gastrointestinal (GI) tract. Potential participants with unknown origin for the neuroendocrine carcinoma in which a gastroenteropancreatic origin is suspected (per pathologist or investigator discretion) will be eligible for the study.~* Tumors must have a Ki-67 index greater than 20% and/or \>20 mitotic figures/10 high-power fields.~* Must have metastatic disease.~* Must measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.~* Any line of treatment (first line versus beyond first line).~* Age \>18 years.~* Life expectancy of greater than 12 weeks.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.~* Must have adequate organ and marrow function.~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Have had chemotherapy or radiotherapy within 3 weeks prior to entering the study.~* Receiving any other investigational agents.~* Untreated brain or meningeal metastases.~* Prior treatment with 5-fluorouracil (5-FU), irinotecan or oxaliplatin.~* Pre-treatment peripheral neuropathy greater than grade 1 per the CTCAE, version 4.0.~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* A secondary primary cancer (excluding baso/squamous cell carcinoma of skin) within 1 year.~* Active viral hepatitis or autoimmune hepatitis. The work-up to confirm active hepatitis or autoimmune hepatitis will only be done if clinical suspicion based on investigator discretion.~* Potential participants with childbearing potential who are not willing to use adequate contraception precautions during the study and for 3 months after stopping study chemotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FOLFIRINOX Treatment (Type: EXPERIMENTAL): Participants will receive modified FOLFIRINOX which consists of 85 mg/m\^2 of oxaliplatin, 400 mg/m\^2 of leucovorin over the first 2 hours, 165 mg/m\^2 of irinotecan in a 90-minute infusion on day 1, followed by a continuous, 46-hour infusion of 5-FU at a dosage of 2,400 mg/m\^2. A cycle will be repeated every 14 days. Granulocyte colony-stimulating factor (G-CSF) prophylaxis will be allowed after each cycle. Participants will undergo re-staging studies every 8 weeks. Participants will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).